Sort   by:  
 Page size 
UnknownClinical, environmental, and genetic risk factors for substance use disorders: characterizing combined effects across multiple cohorts.
Substance use disorders (SUDs) incur serious social and personal costs. The risk for SUDs is complex, with risk factors ranging from social conditions to individual genetic variation. We examined whether models that include a clinical/environmental risk index (CERI) and polygenic scores (PGS) are ab...
S-EPMC9938102 | biostudies-literature
Unknown20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

Background

The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side e...
S-EPMC5734609 | biostudies-literature
UnknownPosttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study.

Background

The Primary Immune Deficiency Treatment Consortium (PIDTC) enrolled children in the United States and Canada onto a retrospective multicenter natural history study of hematopoietic cell transplantation (HCT).

Objective

We investigated outcomes of HCT for severe combined imm...
S-EPMC11294800 | biostudies-literature
UnknownA Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.

Background

LY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients with coronavirus disease 2019 (Covid-19). Data are needed on the effect of this antibody in patie...
S-EPMC7781100 | biostudies-literature
UnknownPathogenic UNC13A variants cause a neurodevelopmental syndrome by impairing synaptic function.
The UNC13A gene encodes a presynaptic protein that is crucial for setting the strength and dynamics of information transfer between neurons. Here we describe a neurodevelopmental syndrome caused by germline coding or splice-site variants in UNC13A. The syndrome presents with variable degrees of deve...
S-EPMC12597829 | biostudies-literature
UnknownGenetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge.
Glucose levels 2 h after an oral glucose challenge are a clinical measure of glucose tolerance used in the diagnosis of type 2 diabetes. We report a meta-analysis of nine genome-wide association studies (n = 15,234 nondiabetic individuals) and a follow-up of 29 independent loci (n = 6,958-30,620). W...
S-EPMC2922003 | biostudies-literature
UnknownGenetic determinants of telomere length from 109,122 ancestrally diverse whole-genome sequences in TOPMed.
Genetic studies on telomere length are important for understanding age-related diseases. Prior GWAS for leukocyte TL have been limited to European and Asian populations. Here, we report the first sequencing-based association study for TL across ancestrally-diverse individuals (European, African, Asi...
S-EPMC9075703 | biostudies-literature
UnknownGenetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.
Multiple sclerosis is a common disease of the central nervous system in which the interplay between inflammatory and neurodegenerative processes typically results in intermittent neurological disturbance followed by progressive accumulation of disability. Epidemiological studies have shown that gene...
S-EPMC3182531 | biostudies-literature
UnknownEfficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.

Background

We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with...
S-EPMC8700279 | biostudies-literature
UnknownResponses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.

Background

In a randomized, placebo-controlled, clinical trial, bamlanivimab, a SARS-CoV-2-neutralizing monoclonal antibody, given in combination with remdesivir, did not improve outcomes among hospitalized patients with COVID-19 based on an early futility assessment.

Objective

To eva...
S-EPMC9334931 | biostudies-literature
Sort   by:  
 Page size